Clinical Takeaway
Randomized controlled trial evidence through mid-2025 shows that cannabinoids provide measurable but modest pain relief for chronic pain conditions, with effects varying based on THC-to-CBD ratio, cannabinoid source, and delivery method. The strength of that evidence remains limited, meaning clinicians should weigh potential benefits against known harms on an individual patient basis. No single cannabinoid formulation has emerged as a clear standard of care for chronic pain management.
#1 Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Citation: Chou Roger et al.. Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.. Annals of internal medicine. 2026. PMID: 41429020.
Design: 5 Journal: 3 N: 4 Recency: 3 Pop: 2 Human: 1 Risk: -2
This updated systematic review addresses a critical evidence gap regarding cannabinoid efficacy and safety in chronic pain management, where clinical guidance remains limited by heterogeneous trial data and unclear risk-benefit profiles. By synthesizing randomized controlled trials and applying rigorous bias assessment, this work provides clinicians with contemporary, high-quality evidence to inform prescribing decisions for a patient population with significant unmet analgesic needs. The stratification of cannabinoids by THC-to-CBD ratios offers practical pharmacological differentiation that may guide individualized treatment selection based on therapeutic targets and adverse effect tolerability.
Quality Gate Alerts:
- Preclinical only
Abstract: BACKGROUND: Benefits and harms of cannabinoids for chronic pain are uncertain. PURPOSE: To update an evidence synthesis on cannabinoids for chronic pain. DATA SOURCES: Ovid MEDLINE, PsycINFO, Embase, the Cochrane Library, and Scopus to 28 July 2025. STUDY SELECTION: Randomized placebo-controlled trials. DATA EXTRACTION: Data extraction, risk of bias, and strength of evidence were dually reviewed. Cannabinoids were categorized by tetrahydrocannabinol (THC)-to-cannabidiol (CBD) ratio (high, comparable, or low), source (synthetic, purified, extracted), and administration method. DATA SYNTHESIS: 25 short-term (1 to 6 months) randomized controlled trials (n = 2303; 64% neuropathic pain) assessed cannabinoids. Oral synthetic/purified high THC-to-CBD (THC only) may slightly reduce and oromucosal, extracted, comparable THC-to-CBD ratio products probably slightly reduce pain severity (pooled differences, -0.78 and -0.54 points, respectively, [0 to 10 scale]), with moderate or large increased dizziness, sedation, and nausea. Among THC-only products, nabilone moderately reduced pain severity but dronabinol did not (pooled differences, -1.59 and -0.23 points, respectively). Low THC-to-CBD interventions may not improve outcomes. Although low THC-to-CBD mixed THC/CBD products may increase dizziness, sedation, and nausea, CBD alone may not increase harms. LIMITATION: Variability within categories; lack of product details; unclear U.S. availability of studied products; restricted to English-language studies. CONCLUSION: Comparable and high THC-to-CBD ratio cannabinoid products may result in small improvements in pain and increased common adverse events during short-term treatment of primarily neuropathic pain; among high-ratio THC-only products, nabilone (but not dronabinol) reduced pain. Low THC-to-CBD products may not improve outcomes. Studies are needed on long-term outcomes and other cannabis product types. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality, U.S
💊 This updated systematic review provides a timely reassessment of cannabinoid efficacy for chronic pain, though clinicians should remain cautious about drawing firm conclusions given the heterogeneity of cannabis products, dosing regimens, and patient populations across trials. The authors’ stratification by THC-to-CBD ratios represents a methodologically sound attempt to parse differential effects, yet real-world cannabis use rarely follows such neat pharmacological categorization, and individual patient response remains highly variable due to factors like baseline endocannabinoid tone, concurrent medications, and delivery methods that trials often cannot fully capture. Notably, many studies remain limited by small sample sizes, short follow-up periods, and the ongoing regulatory barriers that restrict high-quality research in this space, meaning our evidence base still lags behind clinical demand. Rather than viewing cannabinoids as a definitive solution, the practical implication is to consider them as a potential adjunctive tool for carefully selected patients with chronic pain who have exhausted or poorly tolerated conventional options, with